{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:52:31Z","timestamp":1793159551692,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University Research Federation"},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>There is conflicting evidence as to whether patients with pre-existing heart failure (HF) are at increased risk of developing cancer, especially because of common risk factors. We aimed to assess the incidence of cancer in patients with pre-existing HF compared with patients without known HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The French National Administrative Health Data System, containing all healthcare information for 99% of the French population, was used to identify adult patients with a first diagnosis of HF between 2010 and 2019 and without a history of cancer before HF diagnosis. HF patients were matched for sex and age to HF-free and cancer-free individuals (3:1 ratio). We found 330 867 HF patients, and 992 601 matched controls (54.7% women, mean age 77.7 \u00b1 13.5 years). A first cancer was diagnosed in 28 151 (8.5%) HF patients over a mean follow-up of 4.3 \u00b1 2.8 years compared with 77 325 (7.8%) in the controls over 4.9 \u00b1 2.8 years of follow-up (unadjusted sub-distribution hazard ratio, sHR: 1.12 [1.11\u20131.13], P &amp;lt; 0.001). The higher risk of new cancer in HF patients remained after full adjustment for major comorbidities, age, sex, year of diagnosis, region of residence, tobacco use, and alcohol consumption (adjusted sHR = 1.06, [1.04\u20131.07]; P &amp;lt; 0.0001). Overall, the calculated attributable risk of new cancer after HF was 16.5% (13.3.9\u201320.4%). This increased risk was observed for most solid malignancies (especially colorectal and lung cancer), and for multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with a history of HF have a higher risk of developing cancer than the general population. Cancer screening strategies should be advocated in patients with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf152","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T08:26:17Z","timestamp":1742286377000},"page":"289-296","source":"Crossref","is-referenced-by-count":7,"title":["Increased cancer incidence in patients with pre-existing heart failure: results from a French nationwide cohort study"],"prefix":"10.1093","volume":"33","author":[{"given":"Mariana","family":"Mirabel","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, PARCC , F-75015 Paris ,","place":["France"]},{"name":"Department of Cardiology, Institut Mutualiste Montsouris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Nevoret","sequence":"additional","affiliation":[{"name":"CEMKA , Bourg-la-Reine ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orianne","family":"Domeng\u00e9","sequence":"additional","affiliation":[{"name":"CIC1418 and DMU CARTE, AP-HP, H\u00f4pital Europ\u00e9en Georges-Pompidou , F-75015, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Emery","sequence":"additional","affiliation":[{"name":"CEMKA , Bourg-la-Reine ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"De Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1469-7772","authenticated-orcid":false,"given":"Jean-Philippe","family":"Empana","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, PARCC , F-75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-6117","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Hulot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, PARCC , F-75015 Paris ,","place":["France"]},{"name":"CIC1418 and DMU CARTE, AP-HP, H\u00f4pital Europ\u00e9en Georges-Pompidou , F-75015, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2026020218524531700_zwaf152-B1","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the translational research committee of the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026020218524531700_zwaf152-B2","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026020218524531700_zwaf152-B3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026020218524531700_zwaf152-B4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41467-024-45307-x","article-title":"Causes of death among people living with metastatic cancer","volume":"15","author":"Mani","year":"2024","journal-title":"Nat Commun"},{"key":"2026020218524531700_zwaf152-B5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurjpc\/zwad210","article-title":"Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO registry insights","volume":"30","author":"Shibata","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026020218524531700_zwaf152-B6","doi-asserted-by":"crossref","first-page":"e013754","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: cancer development in patients with cardiovascular disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026020218524531700_zwaf152-B7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/eurjpc\/zwae089","article-title":"Association of inflammatory markers with incident heart failure or cancer in the HUNT3 and Health ABC population studies","volume":"31","author":"Bertero","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026020218524531700_zwaf152-B8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"2026020218524531700_zwaf152-B9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: a long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026020218524531700_zwaf152-B10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to Pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026020218524531700_zwaf152-B11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jacc.2018.01.069","article-title":"Lack of association between heart failure and incident cancer","volume":"71","author":"Selvaraj","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026020218524531700_zwaf152-B12","doi-asserted-by":"crossref","first-page":"oead073","DOI":"10.1093\/ehjopen\/oead073","article-title":"Association between heart failure and the incidence of cancer: a systematic review and meta-analysis","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2026020218524531700_zwaf152-B13","author":"SNDS Health Data Hub"},{"key":"2026020218524531700_zwaf152-B14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026020218524531700_zwaf152-B15","author":"Caisse Nationale Assurance Maladie"},{"key":"2026020218524531700_zwaf152-B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.amjcard.2022.06.013","article-title":"The interaction effect of cardiac and noncardiac co-morbidities on mortality rates in patients with heart failure","volume":"179","author":"Villadsen","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026020218524531700_zwaf152-B17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026020218524531700_zwaf152-B18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.120.053315","article-title":"From studying heart disease and cancer simultaneously to reverse cardio-oncology","volume":"144","author":"de Wit","year":"2021","journal-title":"Circulation"},{"key":"2026020218524531700_zwaf152-B19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation"},{"key":"2026020218524531700_zwaf152-B20","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.18632\/oncotarget.9409","article-title":"Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"2026020218524531700_zwaf152-B21","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"},{"key":"2026020218524531700_zwaf152-B22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1078-0432.CCR-22-2598","article-title":"CHIP happens: clonal hematopoiesis of indeterminate potential and its relationship to solid tumors","volume":"29","author":"Reed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026020218524531700_zwaf152-B23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020218524531700_zwaf152-B24","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","article-title":"Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction","volume":"77","author":"Pascual-Figal","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026020218524531700_zwaf152-B25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026020218524531700_zwaf152-B26","doi-asserted-by":"crossref","first-page":"e026953","DOI":"10.1161\/JAHA.122.026953","article-title":"Circulating androgen concentrations and risk of incident heart failure in older men: the cardiovascular health study","volume":"11","author":"Njoroge","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026020218524531700_zwaf152-B27","doi-asserted-by":"crossref","first-page":"e008755","DOI":"10.1161\/CIRCHEARTFAILURE.121.008755","article-title":"Testosterone, hypogonadism, and heart failure","volume":"15","author":"Di Lodovico","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026020218524531700_zwaf152-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2021.09.008","article-title":"Reverse cardio-oncology: exploring the effects of cardiovascular disease on cancer pathogenesis","volume":"163","author":"Koelwyn","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026020218524531700_zwaf152-B29","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026020218524531700_zwaf152-B30","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf152\/62492456\/zwaf152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/2\/289\/62492456\/zwaf152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/2\/289\/62492456\/zwaf152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:53:01Z","timestamp":1770076381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/2\/289\/8088147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf152","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,3,20]]}}}